[HTML] cell.comFull View

[HTML][HTML] Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - cell.com
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …
被引用次数：156 相关文章

[引用][C] Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell - folia.unifr.ch
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in
Ovarian Cancer SONAR logo Log in Sign up EN English Français Deutsch Italiano Back Full-text …

Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - edoc.mdc-berlin.de
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …
[HTML] nih.gov

[HTML][HTML] Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - ncbi.nlm.nih.gov
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - …, 2018 - mayoclinic.elsevierpure.com
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …
[HTML] sciencedirect.com

[HTML][HTML] Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - Elsevier
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - hero.epa.gov
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell, 2018 - pure.mpg.de
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …

[引用][C] Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

F Coscia, E Lengyel, J Duraiswamy, B Ashcroft… - Cell - sonar.ch
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in
Ovarian Cancer SONAR logo Log in Sign up EN English Français Deutsch Italiano Back Full-text …

Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer

F Coscia, L Ernst, J Duraiswamy - Cell, 2018 - dialnet.unirioja.es
Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-
based chemotherapy and recur, but 15% remain disease free over a decade. To discover …